We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 03, 2021

Ipilimumab Alone or Ipilimumab Plus Anti–PD-1 Therapy in Patients With Metastatic Melanoma Resistant to Anti–PD-(L)1 Monotherapy

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Ipilimumab Alone or Ipilimumab Plus Anti-PD-1 Therapy in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy: A Multicentre, Retrospective, Cohort Study
Lancet Oncol 2021 May 11;[EPub Ahead of Print], I Pires da Silva, T Ahmed, ILM Reijers, AM Weppler, A Betof Warner, JR Patrinely, P Serra-Bellver, C Allayous, J Mangana, K Nguyen, L Zimmer, C Trojaniello, D Stout, M Lyle, O Klein, CL Gerard, O Michielin, A Haydon, PA Ascierto, MS Carlino, C Lebbe, P Lorigan, DB Johnson, S Sandhu, SN Lo, CU Blank, AM Menzies, GV Long

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading